Please assess the completion status of the following clinical trial:

Trial Title: Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with complete resection who are at TNM (primary tumor, regional nodes, metastasis) stage II-Ⅲa, postoperative pathology confirmed for non-small cell lung cancer;~* Has completed four cycle standard solution of adjuvant chemotherapy, or refused to accept the postoperative adjuvant chemotherapy;~* Patients between 18 and 70 years old, no gender restriction;~* Eastern Cooperative Oncology Group (ECOG) PS of two or less;~* Before the start of the study, patient fully understands the study and is willing to sign the informed consent form;~Exclusion Criteria:~* Receiving adjuvant chemotherapy patients started greater than 24 weeks from surgical resection;~* Refused adjuvant chemotherapy patients started greater than 8 weeks from surgical resection;~* Suspected malignant pleural effusion;~* There is no clear pathological diagnosis;~* Combined with other cancer;~* Patient have a positive surgical margin;~* Accept other treatment for lung cancer of postoperative；~* Combined with severe idiopathic disease of liver, kidney and hematopoietic system;~* Combined psychosis or AIDS;~* Allergy to the test drug;~* Pregnant or lactating women;~* Participation in any other clinical trial within three months;~* Conditions that are considered not suitable for this study investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Huaier Granule (Type: EXPERIMENTAL): Huaier Granule
- placebo (Type: PLACEBO_COMPARATOR): placebo
- No-treatment Control (Type: NO_INTERVENTION): patients refused any treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).